CD19 and B-cell acute lymphoblastic leukemia: Blinatumomab (CD3 ×B lymphocyte antigen CD19) used for the treatment of B-cell acute lymphoblastic leukemia is an effective and advanced bispecific antibody (Lim et al., 2021).